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Abstract
Background
High tuberculosis (TB) burden countries should consider systematic screening among
adults in the general population. We identified symptom screening rules to be used in addi-
tion to cough2 weeks, in a context where X-ray screening is not feasible, aiming to
increase the sensitivity of screening while achieving a specificity of85%.
Methods
We used 2010 Zambia South Africa Tuberculosis and HIV/AIDS Reduction (ZAMSTAR)
survey data: a South African (SA) training dataset, a SA testing dataset for internal valida-
tion and a Zambian dataset for external validation. Regression analyses investigated rela-
tionships between symptoms or combinations of symptoms and active disease. Sensitivity
and specificity were calculated for candidate rules.
Results
Among all participants, the sensitivity of using only cough2 weeks as a screening rule was
less than 25% in both SA and Zambia. The addition of any three of six TB symptoms (cough
<2 weeks, night sweats, weight loss, fever, chest pain, shortness of breath), or 2 or more of
cough <2 weeks, night sweats, and weight loss, increased the sensitivity to ~38%, while
reducing specificity from ~95% to ~85% in SA and ~97% to ~92% in Zambia. Among HIV-
negative adults, findings were similar in SA, whereas in Zambia the increase in sensitivity
was relatively small (15% to 22%).
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Conclusion
High TB burden countries should investigate cost-effective strategies for systematic screen-
ing: one such strategy could be to use our rule in addition to cough2 weeks.
Introduction
A person presumed to have pulmonary tuberculosis (TB) is currently defined as someone with
an unexplained cough for2 weeks or with unexplained findings on chest radiograph sugges-
tive of TB [1], irrespective of their HIV status or any other individual characteristic. Systematic
screening for active TB in the community tends to find more cases earlier in the disease pro-
gression compared to when symptomatic patients seek healthcare [2]. A systematic review [3]
developed a standardized screening rule for excluding TB in individuals who are human
immunodeficiency virus (HIV) positive in resource poor environments with the primary aim
of achieving a high negative predictive value, which would allow initiation of isoniazid preven-
tive therapy (IPT) to few “false negative” TB cases. The rule indicated an HIV-positive individ-
ual with any of current cough, night sweats, weight loss or fever should not be offered IPT
before further investigation for TB. This rule is now part of World Health Organization
(WHO) guidelines [4].
To date, few TB prevalence surveys from high HIV burden settings in sub-Saharan Africa
have been used to evaluate symptom screening rules. A western Kenyan survey showed a sensi-
tivity of 41% and 82% respectively for cough2 weeks and any TB symptom (cough, haemop-
tysis, fever, night sweats, weight loss, of any duration or severity) amongst HIV-negative
individuals, and 69% and 96% respectively among HIV-positive individuals [5]. Specificity
could not be stratified by HIV status (HIV status of TB negative individuals was not collected)
and was 89% and 32% respectively for cough2 weeks and any TB symptom. However, in
this survey, sputum cultures were only conducted if a participant was screened positively by
symptom, smear or chest x-ray. The Zambia South Africa Tuberculosis and HIV/AIDS Reduc-
tion (ZAMSTAR) prevalence surveys [6–8] are unusual: all participants provided a sputum
sample for culture, irrespective of TB symptoms and without X-ray screening. These surveys
provide an opportunity to investigate the performance of alternative symptom screening rules
in a high TB/HIV burden setting although it is expected that sensitivity would be lower than
for the Kenyan survey for instance, because all participants had sputum cultures and not only
those with a positive screen.
The impact of systematic screening on the epidemiology of TB depends on the frequency of
screening and the sensitivity of the screening method [9]. For instance, when screening annu-
ally using a method with 50% sensitivity, the transmission rate could be decreased by up to
27%, depending on the cure rate and the case detection rate. Currently there is emphasis on
systematic screening in programmatic settings in order to identify more TB cases earlier [10].
Since cough2 weeks is used as the screening symptom, for our analysis we focused on the
group not eligible for screening or diagnostic algorithms. We used ZAMSTAR data to develop
symptom screening rules for the general population regardless of HIV status and for the HIV-
negative population with the aim to increase screening but not diagnostic accuracy. We describe
how the rules to be used in addition to cough2 weeks were developed and validated, to increase
the sensitivity of systematic screening in a high TB/HIV burden setting while at the same time
achieving a specificity of at least 85%. We chose 85% on the basis that it would not be feasible to
implement screening if>15% of the population screened positive, and were thus eligible for fur-
ther investigation for TB, among those without TB, i.e. to ensure some limit on the programmatic
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resources that would be required to manage “false-positive” cases. The choice was also made in
the context that in our setting the currently recommended screening rule of cough> = 2 weeks
had a specificity of ~95%, so our choice corresponded to an aim to identify a rule for which speci-
ficity was< = 10% lower than the currently recommended screen.
Methods
Case definition
A case of culture positive prevalent TB was defined as a participant who had a positive culture
for Mycobacterium tuberculosis (M.tb). One sputum sample collected from each participant
was split and cultured in two Mycobacteria Growth Indicator Tubes (Becton, Dickinson and
Company, Franklin Lakes, New Jersey, US) [6]. Positive cultures were speciated according to
the study algorithm as M.tb. A speciated non-tuberculous mycobacterium was defined not to
be TB. Participants whose sample was lost, or for whom both cultures were contaminated,
were excluded.
Setting and study population
Twenty-four communities were surveyed (eight in SA and 16 in Zambia) in a TB/HIV preva-
lence survey conducted in 2010 to measure the primary endpoint of the ZAMSTAR trial [6–8].
All individuals aged18 years who stayed in households in the previous 24 hours were asked
to participate. All participants had a respiratory secretion sample collected. 90,601 participants
were enrolled and 894 cases were diagnosed out of 64,463 participants whose sputum sample
was evaluable for M.tb, 702/30,017 in SA and 192/34,446 in Zambia. In Zambia, the average of
the 16 community-specific prevalences was 555/100,000 among participants with an evaluable
sample (range 221 to 1,095/100,000). In SA, the average of the eight community-specific preva-
lences was 2,338/100,000 among participants with an evaluable sample (range 1,489 to 3,103/
100,000).
Data collection
A structured questionnaire was used by trained, supervised research assistants to collect socio-
demographic information and to elicit symptoms from participants. Each participant was
asked if they had a current cough, and if yes they were asked for how many weeks they had
been coughing. It was therefore possible to distinguish participants who had a cough of2
weeks. Other symptoms included currently producing phlegm/sputum or blood, current
shortness of breath, sweating at night or fever and weight loss within the past month.
A respiratory secretion sample was collected on the spot spontaneously or with the assis-
tance of breathing techniques. The laboratory algorithm has been described elsewhere [6].
HIV testing was done on all participants who consented, using rapid HIV test kits and a fin-
ger-prick sample. Participants were also asked to self-report their HIV status if known. If par-
ticipants did not give consent to be tested for HIV, their self-reported HIV status was used in
the analysis.
Data analysis
The screening rules were developed and internally validated for symptomatic participants in
addition to cough2 weeks by randomly dividing the SA dataset into equal sized training and
testing datasets, and then externally validated with the Zambian data to comply with the “pre-
sumed TB case” definition recommended by WHO. Six symptoms, namely cough <2 weeks,
night sweats, fever, chest pain, weight loss and shortness of breath, were investigated for
Screening rules for TB in high burden settings
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association with prevalent TB among participants without a cough2 weeks. Logistic regres-
sion was used to identify which of these symptoms, or combinations of these symptoms, were
associated with prevalent TB in the South African dataset (results shown in supporting infor-
mation). The association of different counts of symptoms, still excluding those with cough2
weeks, were similarly investigated: first among all six TB symptoms, second restricted to the
four symptoms considered in the 2013 WHO guidelines [4] (cough, night sweats, weight loss
and fever), and third restricted to three of these four symptoms which were most strongly asso-
ciated with prevalent TB in this dataset–cough, night sweats and weight loss. From these analy-
ses, a few alternative candidate screening rules were identified, i.e. that met our pre-specified
criteria of having a specificity of at least 85%.
Using only the training dataset, the overall values of sensitivity and specificity for each can-
didate screening rule used in combination with cough2 weeks were calculated. We calcu-
lated 95% confidence intervals based on bootstrapping of the data, stratified on community
and with clustering by census enumeration area, to account for the sampling design. We
repeated the calculation of sensitivities and specificities with the SA testing dataset for internal
validation and with the Zambian dataset for external validation of the alternative rules. We
then repeated the calculation of sensitivities and specificities of the screening rules, but with
restriction to HIV-negative participants. We also repeated the analyses with restriction to
HIV-positive participants for completeness—these analyses are not included because WHO
guidelines for TB screening among HIV-positive individuals are established based on a meta-
analysis of various studies including the data from the HIV-positive participants in the 2005
ZAMSTAR Zambian survey [7] which made up 27% of the weight of the meta-analysis [3].
Ethics
Stellenbosch University, the University of Zambia and the London School of Hygiene and Trop-
ical Medicine gave ethics approval. Written informed consent was obtained from participants.
Results
Among all 90,601 participants, age and gender were recorded for 98.7% (57,075/57,089) in
Zambia and 99.9% (32,770/32,792) in SA; among these the percentages who gave a blood sam-
ple for HIV testing were 67.1% (38,300/57,075) and 34.0% (11,147/32,770) respectively. For
each community, HIV prevalence among participants who gave a blood sample for HIV test-
ing was age-sex standardized to the overall participant population. In Zambia, the average of
the 16 community-specific prevalences was 17.1% (range 8.1% to 26.6%). In SA, the average of
the eight community-specific prevalences was 18.3% (range 14.2% to 22.9%).
Among participants with a sputum sample that was evaluable for M.tb (n = 64,463), 10,165/
30,017 from SA and 23,480/34,446 from Zambia gave a blood sample for HIV testing. There
were no missing data on reported symptoms, since electronic data capture forced a yes or no
answer. There were missing data on duration of cough (3.1%) and these participants were
removed from analyses.
18,414/30,017 participants from SA and 28,990/34,446 participants from Zambia either
gave a blood sample for HIV testing or reported they had previously tested for HIV and
reported their HIV status based on their most recent HIV test; the percentages who were HIV-
positive were 16.1% (2,965/18,414) in SA and 17.2% (4,974/28,990) in Zambia. In SA, 144/
1,670 (8.6%) with a cough2 weeks had TB compared with 555/28,289 (2.0%) without a
cough2 weeks (OR 4.7, 95%CI 4.0–5.5) while in Zambia, 46/1,175 (3.9%) with a cough2
weeks had TB compared with 143/33,132 (0.4%) without a cough2 weeks (OR 9.4, 95% con-
fidence interval 6.6–13.4).
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In Table 1 the SA and Zambian surveys are compared, showing the demographics of partic-
ipants regardless of HIV status and of participants known to be HIV negative. In the entire SA
sample for those participants regardless of HIV status, the TB prevalence was highest among
participants who currently coughed (6.0%), followed by recent unintentional weight loss
(5.0%) and current shortness of breath (4.8%). In Zambia, the TB prevalence was highest
among participants who had current fever (2.5%), followed by current night sweats (2.1%) and
current cough (2.1%). In SA, the highest TB prevalence among participants known to be HIV
negative was for those who currently coughed (5.3%), followed by recent unintentional weight
loss (4.3%) and current night sweats (4.2%). In Zambia, the highest prevalence was among
those who had current shortness of breath (1.2%), followed by current chest pains (1.1%) and
current cough (1.0%).
When considering a count of symptoms (Table 2), in the entire SA sample, the TB preva-
lence was highest among participants regardless of HIV status who had 3 of cough <2 weeks,
night sweats or weight loss (CSW) (7.5%), followed by 4 of cough <2 weeks, night sweats,
fever or weight loss (CSFW) (6.9%). In Zambia, the TB prevalence was highest among partici-
pants who had 4 of CSFW (3.9%), followed by 3 out of 6 symptoms (2.5%). In SA, the highest
TB prevalence among participants known to be HIV negative was for those who had 3 of CSW
(5.1%), followed by 4 of CSFW (4.3%). In Zambia, the highest prevalence was among those
who had 4 of CSFW (3.4%), followed by 3 of CSW (1.5%).
Table 3 shows the sensitivity and specificity for all screening rules that were considered
using the training dataset, separately for each of the training, testing, and validation datasets.
Fig 1 shows sensitivity and specificity for 3 screening rules that met pre-specified criteria (spec-
ificity85%) in the SA training dataset, as well as for a few alternative screening rules that
were relatively close to meeting pre-specified criteria. Including all participants regardless of
HIV status, using cough2 weeks to identify those who should be further investigated for TB
had a sensitivity of 21% (95%CI 17–26%) in the SA training dataset, a sensitivity of 20% (95%
CI 16–24%) in the SA testing dataset and 24% (95%CI 18–30%) in Zambia, with specificity of
95% in SA (training and testing), and 97% in Zambia. Adding three or more of six TB symp-
toms or 2 or more of cough <2 weeks, night sweats or weight loss (CSW) to this screen
increased sensitivity to 38% (95%CI 33–43%) in SA (training), 37% (95%CI 32–42%) in SA
(testing) and 40% (95%CI 32–46%) in Zambia, with specificity falling to 85% (SA training and
testing) and 92% (Zambia).
In participants known to be HIV negative using cough2 weeks to identify those who
should be further investigated for TB had a sensitivity of 26% (95%CI 19–33%) in the SA train-
ing dataset, a sensitivity of 22% (95%CI 16–29%) in the SA testing dataset and 15% (95%CI
8–23%) in Zambia, with specificity of about 95% in SA (training and testing) and 97% in Zam-
bia. Adding three or more of six TB symptoms or 2 or more of CSW to this screen increased
sensitivity to 42% (95%CI 34–50%) in SA (training), 41% (95%CI 34–49%) in SA (testing) and
22% (95%CI 14–31%) in Zambia, with specificity falling to 84% (SA training), 85% (SA testing)
and 93% (Zambia).
Discussion
WHO systematic screening algorithms for active TB include an interview about HIV status
especially in settings with a high HIV prevalence [11]. Our analysis, for HIV-negative individu-
als, contributes information about symptom screening rules in addition to cough2 weeks in a
setting where TB prevalence is high in the general population and not only among risk groups.
Few studies have used TB prevalence survey data to develop symptom screening rules for
use in the general population—there is a scarcity of data from settings with both high TB and
Screening rules for TB in high burden settings
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Table 1. Demographics of ZAMSTAR prevalence survey participants in South Africa and Zambia, 2010.
South Africa Zambia
All participants, regardless of HIV status
Total TB disease % Total TB disease %
Total 30017 702 2.3% 34446 192 0.6%
Sex Male 11297 333 2.9% 11638 92 0.8%
Female 18720 369 2.0% 22808 100 0.4%
Age 15–24 8819 169 1.9% 12169 45 0.4%
25–34 9167 197 2.1% 10129 82 0.8%
35–44 5577 141 2.5% 5196 42 0.8%
45–54 3480 107 3.1% 3154 12 0.4%
55+ 2974 88 3.0% 3798 11 0.3%
Current cough No 26152 469 1.8% 30444 106 0.3%
Yes 3865 233 6.0% 4002 86 2.1%
Duration of cough <2 weeks 2137 86 4.0% 2688 37 1.4%
> = 2 weeks 1670 144 8.6% 1175 46 3.9%
Unknown duration 58 3 5.2% 139 3 2.2%
Current fever No 24451 522 2.1% 32578 145 0.4%
Yes 5566 180 3.2% 1868 47 2.5%
Current shortness of breath No 27444 578 2.1% 32375 151 0.5%
Yes 2573 124 4.8% 2071 41 2.0%
Current night sweats No 25159 484 1.9% 32431 150 0.5%
Yes 4858 218 4.5% 2015 42 2.1%
Recent unintentional weight loss No 25658 486 1.9% 29979 129 0.4%
Yes 4359 216 5.0% 4467 63 1.4%
Current chest pains No 26865 559 2.1% 31568 140 0.4%
Yes 3152 143 4.5% 2878 52 1.8%
Participants known to be HIV negative
Total TB disease % Total TB disease %
Total 15449 302 2.0% 24016 86 0.4%
Sex Male 5344 144 2.7% 8079 41 0.5%
Female 10105 158 1.6% 15937 45 0.3%
Age 15–24 4738 89 1.9% 9615 30 0.3%
25–34 4470 64 1.4% 6905 34 0.5%
35–44 2749 52 1.9% 2984 12 0.4%
45–54 1809 51 2.8% 1975 3 0.2%
55+ 1683 46 2.7% 2537 7 0.3%
Current cough No 13382 193 1.4% 21490 60 0.3%
Yes 2067 109 5.3% 2526 26 1.0%
Duration of cough <2 weeks 1157 35 3.0% 1774 12 0.7%
> = 2 weeks 873 72 8.2% 666 13 2.0%
Unknown duration 37 2 5.4% 86 1 1.2%
Current fever No 12413 218 1.8% 22865 76 0.3%
Yes 3036 84 2.8% 1151 10 0.9%
Current shortness of breath No 14028 245 1.7% 22730 71 0.3%
Yes 1421 57 4.0% 1286 15 1.2%
Current night sweats No 12902 196 1.5% 22816 77 0.3%
Yes 2547 106 4.2% 1200 9 0.8%
Recent unintentional weight loss No 13117 202 1.5% 21186 71 0.3%
(Continued )
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HIV prevalence. A review on HIV-negative individuals and individuals with unknown HIV
status [12] did not look at individual participant data meta-analysis or the development of a
standardized screening rule, but calculated summary estimates of sensitivity and specificity for
consistent screening definitions across studies: cough of any duration, prolonged cough (2
or3 weeks, depending on the study), and any TB symptom out of3 questions asked. Our
findings were similar to a study in SA miners [13] which showed a sensitivity of around 30%
for 2 out of 3 among CSW but contrasted with findings from Zimbabwe [14], where the symp-
tom screening rule performed better with regards to sensitivity and specificity than any of the
rules from the ZAMSTAR data and the ZAMSTAR rules had worse specificity for a screen of
any TB symptom.
Our study confirmed that symptom screening alone will miss a large proportion of individ-
uals with active prevalent TB in the general population. However, a screening rule of three of
six symptoms, or two of CSW, in addition to cough2 weeks increased the sensitivity of
symptom screening in the general population while maintaining a specificity of84%, in SA
and Zambia. The rationale for maintaining a specificity of84% is simple: a high specificity
limits the number of individuals whose screening result is false positive and who will be inves-
tigated further for TB with sputum microscopy, culture and/or Xpert MTB/RIF (Cepheid,
Sunnyvale, CA, USA). Increasing the sensitivity of symptom screening should mean that fewer
true cases are missed, ensuring more TB cases are referred for TB treatment, potentially
decreasing transmission within communities [15]. Our screening rule would improve sensitiv-
ity and specificity beyond what is currently used, for example in the HPTN 071 (PopART,
Population effects of Antiretroviral Therapy to reduce HIV transmission) study [16].
Survey participants from an area of Cape Town with a low HIV prevalence [17] were not
tested for HIV, but all had sputum smears, cultures and chest x-rays. The survey showed a low
sensitivity for using any one symptom as a screening rule and concluded that the alternative
use of chest x-rays was essential. This finding was confirmed by the Kenyan survey [5] which
showed a sensitivity of 100% when using chest x-rays combined with symptom screening.
Both studies concluded that symptoms alone were insufficient for screening in a prevalence
survey, but could be valuable as part of active case finding. Our study did not include chest x-
ray data, but demonstrated an increase in sensitivity by using our rule. The purpose of our
screen was to see what can be achieved in a household/community setting where only symp-
tom screening can be done by for instance a community health worker to identify adults at rel-
atively high risk of having TB. It is therefore worth investigating using the rule for systematic
screening in a high TB/HIV setting, since doing chest x-rays on everyone in the general popu-
lation is impractical, especially by community healthcare workers. It is also not programmati-
cally cost-effective, as was shown in Botswana when the cost-effectiveness of symptom
screening alone was compared to symptom screening in combination with chest x-rays [18].
National TB prevalence surveys have been completed in sub-Saharan Africa (e.g. Zambia
and Malawi) and are planned in countries with high TB prevalence (e.g. SA). These surveys
screen according to WHO recommendations (symptom screening and chest X-ray) and diag-
nosis is based on two sputum samples; all surveys use cough2 weeks as part of the screen;
Table 1. (Continued)
Yes 2332 100 4.3% 2830 15 0.5%
Current chest pains No 13753 235 1.7% 22142 66 0.3%
Yes 1696 67 4.0% 1874 20 1.1%
HIV: human immunodeficiency virus; TB: tuberculosis
doi:10.1371/journal.pone.0172881.t001
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some also use other symptoms to determine eligibility for sputum examination. Data from
national TB prevalence surveys in which symptoms beyond cough2 weeks were included as
part of screening (e.g. Malawi survey) are a resource for comparing the performance of alter-
native symptom screening rules.
Table 2. Counts of symptoms in ZAMSTAR prevalence survey participants who did not have a cough2 weeks, in South Africa and Zambia, 2010.
South Africa Zambia
All participants, regardless of HIV status
% with
symptom
Total TB % % with
symptom
Total TB %
Total 28289 555 2.0% 33132 143 0.4%
Count of symptoms 0 64.3% 18190 291 1.6% 72.3% 23952 74 0.3%
1 17.7% 5013 108 2.2% 18.3% 6049 25 0.4%
2 9.7% 2741 63 2.3% 6.1% 2025 21 1.0%
3 4.8% 1352 39 2.9% 2.2% 727 18 2.5%
4
+
3.5% 993 54 5.4% 1.1% 379 5 1.3%
Count of symptoms, among cough <2 weeks, weight loss, night
sweats (CSW)
0 74.1% 20959 336 1.6% 78.7% 26058 81 0.3%
1 18.3% 5169 119 2.3% 17.8% 5894 41 0.7%
2 6.6% 1869 78 4.2% 3.2% 1068 19 1.8%
3 1.0% 292 22 7.5% 0.3% 112 2 1.8%
Count of 4 symptoms, i.e. cough <2weeks, weight loss, night
sweats, fever (CWSF)
0 67.4% 19067 305 1.6% 76.8% 25460 79 0.3%
1 18.8% 5313 118 2.2% 17.8% 5887 32 0.5%
2 9.6% 2708 71 2.6% 4.2% 1384 24 1.7%
3 3.5% 997 47 4.7% 1.1% 350 6 1.7%
4 0.7% 204 14 6.9% 0.2% 51 2 3.9%
Participants known to be HIV negative
% with
symptom
Total TB % % with
symptom
Total TB %
Total 14539 228 1.6% 23264 72 0.3%
Count of symptoms 0 61.9% 8999 107 1.2% 73.4% 17069 50 0.3%
1 19.2% 2788 50 1.8% 18.3% 4252 13 0.3%
2 10.4% 1515 31 2.0% 5.6% 1304 3 0.2%
3 5.0% 723 22 3.0% 1.8% 427 5 1.2%
4
+
3.5% 514 18 3.5% 0.9% 212 1 0.5%
Count of symptoms, among cough <2 weeks, weight loss, night
sweats (CSW)
0 72.7% 10570 127 1.2% 79.9% 18593 55 0.3%
1 19.7% 2864 57 2.0% 17.1% 3987 15 0.4%
2 6.7% 969 37 3.8% 2.7% 619 1 0.2%
3 0.9% 136 7 5.1% 0.3% 65 1 1.5%
Count of 4 symptoms, i.e. cough <2 weeks, weight loss, night
sweats, fever (CWSF)
0 65.3% 9499 112 1.2% 78.1% 18162 54 0.3%
1 20.2% 2934 60 2.0% 17.4% 4048 15 0.4%
2 10.4% 1516 34 2.2% 3.6% 836 2 0.2%
3 3.4% 498 18 3.6% 0.8% 189 0 0.0%
4 0.6% 92 4 4.3% 1.4% 29 1 3.4%
HIV: human immunodeficiency virus; TB: tuberculosis
doi:10.1371/journal.pone.0172881.t002
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Limitations
A limitation of using prevalence survey data, especially the ZAMSTAR surveys where cultures
were done on sputum samples from every participant without confirmation of clinical disease
with chest x-rays, could be transient organism excretion with transient positive cultures [19].
Such participants are usually not ill and although for the purpose of a prevalence estimate, all
culture positive samples are indicative of prevalence, they may not be transmitting M.tb. It is
not possible to know for certain what proportion of culture positive participants has transient
organism excretion, but based on Zambian data it could be 15–20% [7]. In addition, self-
reported data inherently include recall and social desirability biases, which is another limita-
tion of survey methodology, and there could also have been misclassification of some HIV-
positive participants as HIV-negative since not every participant had an HIV test result.
Recommendation
Based on our findings, high TB and HIV burden countries should consider using a symptom
screen of three of six TB symptoms or two or more among cough <2 weeks, night sweats and
weight loss in addition to cough2 weeks in the context of systematic screening in the general
population. In future, national prevalence survey data from other countries could be used to
estimate the performance of alternative screening rules.
Supporting information
S1 File. Individual symptoms as predictors, odds ratios and 95% CI restricted to individuals
without cough2 weeks in South Africa (training data) (Table A). Counts of symptoms as
predictors, odds ratios and 95% CI restricted to individuals without cough2 weeks in South
Africa (training data) (Table B).
(DOCX)
Fig 1. Sensitivity and specificity for selected screening rules in all individuals regardless of HIV status and in HIV negative individuals, in
South Africa and Zambia. Symptoms: cough <2 weeks, night sweats, weight loss, fever, chest pain, shortness of breath; CSW: cough <2 weeks, night
sweats, weight loss; CSWF: cough <2 weeks, night sweats, weight loss, fever.
doi:10.1371/journal.pone.0172881.g001
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